134 related articles for article (PubMed ID: 18425078)
1. Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival.
Kloth JN; Kenter GG; Spijker HS; Uljee S; Corver WE; Jordanova ES; Fleuren GJ; Gorter A
Mod Pathol; 2008 Jul; 21(7):866-75. PubMed ID: 18425078
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer.
Jia X; Shanmugam C; Paluri RK; Jhala NC; Behring MP; Katkoori VR; Sugandha SP; Bae S; Samuel T; Manne U
Oncotarget; 2017 Mar; 8(12):20198-20212. PubMed ID: 28423626
[TBL] [Abstract][Full Text] [Related]
3. Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.
Qiu W; Schönleben F; Li X; Su GH
Cancer Lett; 2007 Jan; 245(1-2):163-70. PubMed ID: 16478646
[TBL] [Abstract][Full Text] [Related]
4. The prognostic role of TGF-β signaling pathway in breast cancer patients.
de Kruijf EM; Dekker TJA; Hawinkels LJAC; Putter H; Smit VTHBM; Kroep JR; Kuppen PJK; van de Velde CJH; Ten Dijke P; Tollenaar RAEM; Mesker WE
Ann Oncol; 2013 Feb; 24(2):384-390. PubMed ID: 23022998
[TBL] [Abstract][Full Text] [Related]
5. Smad4 deficiency in cervical carcinoma cells.
Baldus SE; Schwarz E; Lohrey C; Zapatka M; Landsberg S; Hahn SA; Schmidt D; Dienes HP; Schmiegel WH; Schwarte-Waldhoff I
Oncogene; 2005 Jan; 24(5):810-9. PubMed ID: 15531914
[TBL] [Abstract][Full Text] [Related]
6. PIAS1-modulated Smad2/4 complex activation is involved in zinc-induced cancer cell apoptosis.
Yang N; Zhao B; Rasul A; Qin H; Li J; Li X
Cell Death Dis; 2013 Sep; 4(9):e811. PubMed ID: 24052079
[TBL] [Abstract][Full Text] [Related]
7. Molecular analyses of the 15q and 18q SMAD genes in pancreatic cancer.
Jonson T; Gorunova L; Dawiskiba S; Andrén-Sandberg A; Stenman G; ten Dijke P; Johansson B; Höglund M
Genes Chromosomes Cancer; 1999 Jan; 24(1):62-71. PubMed ID: 9892110
[TBL] [Abstract][Full Text] [Related]
8. Mutation analysis of transforming growth factor beta type II receptor, Smad2, Smad3 and Smad4 in esophageal squamous cell carcinoma.
Osawa H; Shitara Y; Shoji H; Mogi A; Kuwano H; Hagiwara K; Takenoshita S
Int J Oncol; 2000 Oct; 17(4):723-8. PubMed ID: 10995883
[TBL] [Abstract][Full Text] [Related]
9. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
[TBL] [Abstract][Full Text] [Related]
10. SMAD2/3 mediate oncogenic effects of TGF-β in the absence of SMAD4.
Bertrand-Chapel A; Caligaris C; Fenouil T; Savary C; Aires S; Martel S; Huchedé P; Chassot C; Chauvet V; Cardot-Ruffino V; Morel AP; Subtil F; Mohkam K; Mabrut JY; Tonon L; Viari A; Cassier P; Hervieu V; Castets M; Mauviel A; Sentis S; Bartholin L
Commun Biol; 2022 Oct; 5(1):1068. PubMed ID: 36207615
[TBL] [Abstract][Full Text] [Related]
11. Smad inhibitor induces CSC differentiation for effective chemosensitization in cyclin D1- and TGF-β/Smad-regulated liver cancer stem cell-like cells.
Xia W; Lo CM; Poon RYC; Cheung TT; Chan ACY; Chen L; Yang S; Tsao GSW; Wang XQ
Oncotarget; 2017 Jun; 8(24):38811-38824. PubMed ID: 28415588
[TBL] [Abstract][Full Text] [Related]
12. Altered levels of Smad2 and Smad4 are associated with human prostate carcinogenesis.
Perttu MC; Martikainen PM; Huhtala HS; Bläuer M; Tammela TL; Tuohimaa PJ; Syvälä H
Prostate Cancer Prostatic Dis; 2006; 9(2):185-9. PubMed ID: 16550207
[TBL] [Abstract][Full Text] [Related]
13. Differences in Smad4 expression in human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck squamous cell carcinoma.
Báez A; Cantor A; Fonseca S; Marcos-Martinez M; Mathews LA; Muro-Cacho CA; Muñoz-Antonia T
Clin Cancer Res; 2005 May; 11(9):3191-7. PubMed ID: 15867212
[TBL] [Abstract][Full Text] [Related]
14. Examination of Smad2 and Smad4 copy-number variations in skin cancers.
Shao Y; Zhang J; Zhang R; Wan J; Zhang W; Yu B
Clin Transl Oncol; 2012 Feb; 14(2):138-42. PubMed ID: 22301403
[TBL] [Abstract][Full Text] [Related]
15. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.
Fleming NI; Jorissen RN; Mouradov D; Christie M; Sakthianandeswaren A; Palmieri M; Day F; Li S; Tsui C; Lipton L; Desai J; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Zhu HJ; Mariadason JM; Burgess AW; Busam D; Zhao Q; Strausberg RL; Gibbs P; Sieber OM
Cancer Res; 2013 Jan; 73(2):725-35. PubMed ID: 23139211
[TBL] [Abstract][Full Text] [Related]
16. Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer.
Aitchison AA; Veerakumarasivam A; Vias M; Kumar R; Hamdy FC; Neal DE; Mills IG
Prostate; 2008 May; 68(6):661-74. PubMed ID: 18213629
[TBL] [Abstract][Full Text] [Related]
17. Allelic analysis of serous ovarian carcinoma reveals two putative tumor suppressor loci at 18q22-q23 distal to SMAD4, SMAD2, and DCC.
Lassus H; Salovaara R; Aaltonen LA; Butzow R
Am J Pathol; 2001 Jul; 159(1):35-42. PubMed ID: 11438451
[TBL] [Abstract][Full Text] [Related]
18. Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer.
Maliekal TT; Antony ML; Nair A; Paulmurugan R; Karunagaran D
Oncogene; 2003 Jul; 22(31):4889-97. PubMed ID: 12894231
[TBL] [Abstract][Full Text] [Related]
19. Nuclear accumulation of Smad complexes occurs only after the midblastula transition in Xenopus.
Saka Y; Hagemann AI; Piepenburg O; Smith JC
Development; 2007 Dec; 134(23):4209-18. PubMed ID: 17959720
[TBL] [Abstract][Full Text] [Related]
20. SMAD4 as a prognostic marker in colorectal cancer.
Alazzouzi H; Alhopuro P; Salovaara R; Sammalkorpi H; Järvinen H; Mecklin JP; Hemminki A; Schwartz S; Aaltonen LA; Arango D
Clin Cancer Res; 2005 Apr; 11(7):2606-11. PubMed ID: 15814640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
